
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is well-positioned in the biotechnology market with its innovative multi-node inhibition approach for cancer treatment. The company's PIKTOR program, expected to have a higher success rate for endometrial and breast cancer, has a large market opportunity and promising results. However, FTH also faces risks such as potential competition and clinical/regulatory concerns. Thus, it is important to closely monitor the progress of PIKTOR and the company's overall pipeline as well as developments in the broader biotechnology industry.
Bears say
Faeth Therapeutics is facing a number of challenges that may negatively impact their success in developing and commercializing their combination treatment for HR+ metastatic breast cancer and endometrial cancer. These challenges include a lengthy 3-year treatment duration, competition from a new class of treatment, and potential side effects and dosage modifications with their drug PIKTOR. Additionally, their acquisition of KAT6 and development of targeted treatments for PI3K mutant and wild-type tumors may also be risky and costly ventures.
This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares